内克塔治疗

NKTR NASDAQ
35.17
+1.47
+4.36%
已收盘, 17:02 06/18 EDT
开盘
33.80
昨收
33.70
最高
35.43
最低
33.80
成交量
121.15万
成交均量(3M)
156.26万
52周最高
69.76
52周最低
29.22
换手率
0.70%
市值
61.30亿
分时
5日
1月
3月
1年
5年

相关股票

微牛行情栏目提供内克塔治疗 NKTR股票价格,内克塔治疗股票实时行情,公司简介,财报信息,股本结构等,掌握美港股行情走势,开盘价,收盘价,总市值,换手率,市盈率,收益率等数据,及时把握美股港股投资机会。

公司介绍

Nektar Therapeutics is a biopharmaceutical company that discovers and develops medicines in areas of high unmet medical need. The Company's research and development pipeline of new investigational drugs includes treatments for cancer, auto-immune disease and chronic pain. It leverages its chemistry platform to discover and design new drug candidates. These drug candidates utilize its polymer conjugate technology platforms, which are designed to enable the development of new molecular entities that target known mechanisms of action. Its programs include Immuno-oncology (I-O), Immunology, Pain-NKTR-181 and Oncology-ONZEALD. It is developing medicines designed to directly or indirectly modulate the activity of key immune cells, such as cytotoxic T cells and Natural Killer (NK) cells, to increase their numbers and improve their function to recognize and attack cancer cells.
展开 >

最近浏览

名称
价格
涨跌幅